CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 52 enrolled
Drug / intervention
Quadrivalent HPV vaccine +1 morebiological
Likely dose
Quadrivalent HPV vaccine 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02750202
NCT02750202Phase 3Completed

Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts

University of Pretoria·interventional·Posted Apr 25, 2016·Updated Jan 23, 2026

In Brief

A Phase 3 clinical trial evaluating Quadrivalent HPV vaccine and Hepatitis B vaccine for Genital Warts. Completed, enrolled 52 participants across 2 sites.

Detailed Summary

Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in South Africa. Medical and destructive therapy for small warts is generally very effective, however unique problems posed by large or extensive genital warts are not so easily solved and treatment of affected patients remains very challenging. Recurrences are common especially among immune-compromised women. This study will test whether giving the quadrivalent human papilloma virus (HPV) vaccine to women with extensive genital warts prior to surgical treatment will improve outcomes. Investigators hypothesize that pre-treatment with HPV vaccine can play a role in the control of both malignant and benign HPV disease in women with and without HIV infection through stimulation of the antibody response. In addition, HPV types and other associated diseases will be studied in women receiving HPV vaccine and placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenital Warts
CountriesSouth Africa

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 25, 2016
Enrollment StartJul 1, 2018
Primary CompletionJul 31, 2025
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 10.2 years ago

Interventions

Quadrivalent HPV vaccinebiological

Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.

Hepatitis B vaccinebiological

Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.